ArticleThe pharmacogenomics journal2017
Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
S P Gampenrieder et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this papercites it